Docket No.: SER-001 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Seymour Fein

Application No.: 10/706,100 Confirmation No.: 7710

Filed: November 12, 2003 Art Unit: 1654

For: Pharmaceutical compositions including low Examiner: A. D. Kosar

dosages of desmonressin

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Madam:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed after the mailing date of a Final Office Action or Notice of Allowance, whichever occurred first, but on or before payment of the Issue Fee (37 CFR 1.97(d)). Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered.

I hereby certify, pursuant to 37 CFR 1.97(e)(2), that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filling of this Information Disclosure Statement.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In addition, Applicant wishes to inform the Examiner of the following patent applications, including the contents of the file wrappers, the claims, any office actions issued therein, and any Notices of Allowance issued therefor:

Serial No. /	Title	Filing Date	Status
Patent No.			
11/744,615 /	Pharmaceutical Compositions	May 4, 2007	Patented
7,405,203	Including Low Dosages of Desmopressin		
12/173,072	Pharmaceutical Compositions Including Low Dosages of Desmopressin	July 15, 2008	Pending
12/173,074	Pharmaceutical Compositions Including Low Dosages of Desmopressin	July 15, 2008	Pending

Please charge our Deposit Account No. 07-1700 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith to our Deposit Account No. 07-1700, under Order No. SER-001.

Dated: March 5, 2009 Respectfully submitted,

Electronic signature: /Edmund R. Pitcher/

Edmund R. Pitcher

GOODWIN PROCTER LLP Exchange Place Boston, Massachusetts 02109 (617) 570-1000 Attorney for Applicant